<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="1"><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK-933776) in Patients With Alzheimer's Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="1"></Trial><Drug id="57403">GSK-933776A</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>APOE epsilon4; Abeta; Complement factor I; P-tau; tau</Biomarkers><Condition>Alzheimers disease</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>GSK-933776A</Interventions><Reference>106006; 2006-004014-41; BA1106006; NCT00459550</Reference></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>